PRIVILEGED & CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
MEMORANDUM
TO: James Prentice, Partner; Sandra Tung, Partner
FROM: Ryan Kowalski, Lead Associate; Megan Chu, Working Associate
DATE: April 18, 2025
RE: Litigation & Regulatory Due Diligence Summary — Luminex Systems Holdings Inc. and Subsidiaries
MATTER NO.: 1001-00004
CLIENT: Ardent Capital Partners III LP
This memorandum is protected by the attorney-client privilege and constitutes attorney work product. It has been prepared by Calderwood & Harkness LLP at the direction of and for the exclusive use of Ardent Capital Partners III LP and its authorized representatives in connection with the proposed acquisition of Luminex Systems Holdings Inc. This memorandum should not be disclosed to any third party without the prior written consent of Calderwood & Harkness LLP, except as necessary for purposes of the R&W insurance application to Grandview Specialty Insurance Company through Ashbury Risk Advisors LLC, subject to appropriate non-waiver agreements.
Right-click to update Table of Contents
1. Executive Summary
This memorandum summarizes the findings of Calderwood & Harkness LLP's litigation and regulatory due diligence review of Luminex Systems Holdings Inc. ("Luminex Holdings" or the "Company") and its subsidiaries (collectively, the "Luminex Group") in connection with the proposed acquisition of Luminex Holdings by Ardent Capital Partners III LP ("Ardent" or the "Buyer") for an aggregate enterprise value of $2,800,000,000, to be effected through a reverse triangular merger pursuant to the Agreement and Plan of Merger dated March 24, 2025 (the "Merger Agreement"). Under the contemplated structure, a newly formed acquisition subsidiary of Ardent will merge with and into Luminex Holdings, with Luminex Holdings surviving as a wholly owned indirect subsidiary of Ardent.
Scope of Review. Our review encompassed materials produced by Luminex Holdings and its counsel, Caldwell, Raines & Sheppard LLP (Patricia Okonkwo, lead deal partner, and Daniel Feinberg, lead associate), through the virtual data room ("VDR") hosted on Sundial Technologies (Venue) in response to Calderwood & Harkness's comprehensive due diligence request list delivered on March 11, 2025 (the "Request List"). The VDR was supplemented on a rolling basis through April 14, 2025, the date of our most recent review. In addition to the VDR materials, our review incorporated information obtained through supplemental written responses provided by Caldwell, Raines & Sheppard LLP and through management interviews conducted between March 31, 2025, and April 10, 2025, with Dr. Stefan Kessler (Chief Executive Officer), Annelise Gruber (Chief Financial Officer), Priya Ramanathan (General Counsel), and Thomas Vickers (Vice President, Government Programs). We also reviewed publicly available court records and regulatory filings on a sampled basis to corroborate information provided in the VDR.
Entities Covered. The Luminex Group comprises the following entities, each of which was included within the scope of our review:
Luminex Systems AG serves as the principal operating entity and intellectual property holding company for the Luminex Group's flagship "Luminex One" procurement-automation software-as-a-service platform. Luminex US is the primary U.S. operating entity, headquartered at 2100 Reston Gateway Drive, Suite 800, Reston, Virginia 20191, with approximately 1,650 employees in the United States. The remaining subsidiaries conduct regional sales, implementation, and support operations in their respective jurisdictions.
Overall Assessment. Based on our review, we have not identified any litigation or regulatory matter that would, individually or in the aggregate, reasonably be expected to constitute a "Material Adverse Effect" as defined in Section 1.1 of the Merger Agreement. The Luminex Group's litigation profile is generally consistent with that of a technology company of comparable size and scope of operations (FY 2024 consolidated revenue of approximately $487 million; Adjusted EBITDA of approximately $121.8 million). However, we have identified several matters that (a) warrant ongoing monitoring through the anticipated closing, (b) should be considered in the context of the representations and warranties set forth in Articles III and IV of the Merger Agreement, (c) require disclosure on the Seller's disclosure schedules (particularly Schedule 3.9 — Litigation, Schedule 3.10 — Compliance with Laws, and Schedule 3.14 — Taxes), and (d) should be brought to the attention of Ashbury Risk Advisors LLC (Philip Navarro) and Grandview Specialty Insurance Company in connection with the representations and warranties insurance application (Policy No. GSI-RWI-2025-04821). These matters are described in detail in Sections 3 through 6 below and summarized in the attached Exhibits.
In particular, we draw the Partners' attention to the following matters that, while not individually material, warrant heightened monitoring:
(a) The pending contract dispute with Paragon Procurement Solutions Inc. in the Eastern District of Virginia (Section 3.1.1), involving claims totaling approximately $23.4 million and implicating intellectual property rights in certain modules of the Luminex One platform;
(b) The informal inquiry by the Bureau of Industry and Security ("BIS") regarding Luminex's export control classification of certain Luminex One analytics modules (Section 5.1.5), which, if resolved unfavorably, could require reclassification of certain platform features under the Export Administration Regulations and impose additional licensing requirements for non-U.S. deployments;
(c) The unresolved German works council consultation regarding the anticipated post-closing workforce restructuring (Section 3.3), which could give rise to claims or delays if not properly managed in coordination with Wendt Schäfer Rechtsanwälte;
(d) The GDPR-related complaint filed with the Baden-Württemberg data protection authority (Section 5.4), which remains in the preliminary assessment phase and involves allegations of inadequate data processing transparency relating to Veltronix GmbH's employee monitoring software deployment; and
(e) The combined approximately 25% market share in procurement-automation SaaS that would result from the combination of Luminex (~18%) and Ardent's existing Fund II portfolio company, Vectis Solutions LLC (~7%), which may increase the likelihood of a Second Request in the HSR review and has prompted us to recommend close coordination with Elaine Forsythe (Antitrust & Competition) (Section 10.2).
Cross-References. This memorandum should be read in conjunction with the following related memoranda prepared by Calderwood & Harkness LLP:
• Material Contracts Review Memorandum (change-of-control consent analysis covering approximately 340 commercial contracts and 26 enterprise license agreements), prepared by the Corporate Transactions team;
• Employment & Benefits Due Diligence Summary Memorandum, prepared by the Employment & Executive Compensation team;
• IP & Technology Due Diligence Summary Memorandum, prepared by the IP & Technology Transactions team; and
• Tax Structure Memorandum, prepared by Sylvia Hartwell and the Tax team, addressing transfer pricing, withholding tax, and post-closing restructuring considerations.
2. Scope and Methodology
2.1 Documents Reviewed
Our litigation and regulatory due diligence review encompassed the following categories of documents and information, organized by reference to our Request List categories (cross-referenced in Exhibit F):
Litigation Files and Court Records. We reviewed all litigation dockets, court filings, and related correspondence for each pending case involving any Luminex Group entity. This included complaints, answers, counterclaims, motions, court orders, discovery correspondence, mediation and settlement communications, and expert reports to the extent produced in the VDR. For U.S. matters, we conducted independent docket checks through PACER and applicable state court electronic filing systems to verify the accuracy and completeness of the information provided by the Company. For non-U.S. matters, we relied on local counsel summaries supplemented by our review of translated pleadings and correspondence produced in the VDR.
Regulatory Correspondence. We reviewed all letters, notices, subpoenas, civil investigative demands, voluntary disclosure confirmations, and other communications received from or sent to governmental agencies and regulatory bodies within the review period. This included correspondence with the U.S. Department of Justice, Federal Trade Commission, Securities and Exchange Commission, Internal Revenue Service, Department of Defense (including the Defense Contract Audit Agency and the Defense Criminal Investigative Service), Department of Commerce (Bureau of Industry and Security), Office of Foreign Assets Control, state attorneys general offices, the Swiss Financial Market Supervisory Authority (FINMA), the Swiss Federal Data Protection and Information Commissioner (FDPIC), the Swiss State Secretariat for Economic Affairs (SECO), the German Federal Cartel Office (Bundeskartellamt), the German Federal Commissioner for Data Protection and Freedom of Information (BfDI), the Baden-Württemberg data protection authority, the UK Information Commissioner's Office (ICO), HM Revenue & Customs (HMRC), and the Singapore Personal Data Protection Commission (PDPC) and Inland Revenue Authority of Singapore (IRAS).
Company-Maintained Litigation Log and Reserve Schedules. Luminex Holdings maintains an internal litigation management log (the "Litigation Log") that tracks all pending, threatened, and recently resolved legal matters across the Luminex Group. The Litigation Log is maintained by Priya Ramanathan (General Counsel) and was last updated on April 8, 2025. We reviewed the Litigation Log in its entirety and cross-referenced it against the court filings and regulatory correspondence produced in the VDR to identify any gaps or inconsistencies. We also reviewed the reserve schedules maintained by the Company's finance team in consultation with Hargrove Thornton LLP, the Company's independent auditor.
Insurance Policies. We reviewed the following categories of insurance policies maintained by the Luminex Group: (i) commercial general liability insurance; (ii) professional liability / errors and omissions insurance; (iii) cyber liability insurance; (iv) directors' and officers' liability insurance; and (v) employment practices liability insurance. Our review focused on policy limits, deductibles and retentions, coverage terms, key exclusions, and notice requirements, and is summarized in Section 7 and Exhibit E below.
Compliance Program Documentation. We reviewed the Luminex Group's compliance program documentation, including the corporate code of conduct (last revised January 2024), anti-corruption and anti-bribery policies (covering FCPA and UK Bribery Act compliance), data privacy policies (covering GDPR, CCPA/CPRA, Swiss FADP, and Singapore PDPA compliance), export control and sanctions compliance policies, government contract compliance policies, and antitrust/competition law compliance policies. We also reviewed training records, third-party due diligence procedures, and internal audit reports relating to compliance matters.
Officer Certifications and Questionnaires. In connection with the execution of the Merger Agreement, each of the Company's executive officers and directors completed a litigation and regulatory questionnaire. We reviewed the completed questionnaires submitted by Dr. Stefan Kessler (CEO), Annelise Gruber (CFO), Priya Ramanathan (General Counsel), Thomas Vickers (VP, Government Programs), Dr. Marcus Oettinger (CTO), and the members of the Board of Directors of Luminex Holdings.
Auditor Communications. We reviewed the communications from Hargrove Thornton LLP (lead audit partner Margaret Dawson) to the Audit Committee of the Board of Directors of Luminex Holdings regarding contingent liabilities and litigation reserves for the fiscal years ended December 31, 2023, and December 31, 2024. We also reviewed the management representation letters issued by Luminex management to Hargrove Thornton LLP in connection with the annual audits, as well as the legal representation letters (commonly known as "audit response letters") issued by Caldwell, Raines & Sheppard LLP and Luminex's other outside counsel in response to auditor inquiries pursuant to ABA Statement of Policy Regarding Lawyers' Responses to Auditors' Requests for Information.
Disclosure Schedules. We reviewed the draft disclosure schedules prepared by Caldwell, Raines & Sheppard LLP on behalf of the Seller, as delivered to Calderwood & Harkness on April 4, 2025, and the revised drafts delivered on April 12, 2025. Our comments on the disclosure schedules were delivered to Daniel Feinberg of Caldwell, Raines & Sheppard LLP on April 15, 2025, and we are awaiting the Seller's responses.
2.2 Jurisdictions Covered
Our review covered the following jurisdictions, which correspond to the jurisdictions in which the Luminex Group maintains legal entities, conducts material business operations, or is subject to regulatory oversight:
• United States (federal and state): Federal courts and regulatory agencies; state courts and regulatory agencies in Virginia (principal place of business), Delaware (state of incorporation), California (significant customer base and employee population of approximately 280 employees in San Francisco and San Jose offices), New York (financial operations and customer relationships), and other states as indicated by nexus analysis.
• Switzerland (Canton of Glenrock Assurance): Courts of competent jurisdiction in the Canton of Glenrock Assurance; FINMA; FDPIC; SECO; Swiss Federal Tax Administration; cantonal tax authorities.
• Germany (Munich, Bavaria): Munich District Court and Higher Regional Court; German Federal Cartel Office (Bundeskartellamt); BfDI and state-level data protection authorities; Finanzamt München; Munich Labor Court (for employment matters).
• United Kingdom (England and Wales): High Court of Justice; Employment Tribunals; ICO; HMRC; Companies House.
• Singapore: Singapore High Court; PDPC; IRAS; Accounting and Corporate Regulatory Authority (ACRA).
• European Union (regulatory matters): European Commission (competition and foreign subsidies review); EU data protection authorities (cross-border GDPR enforcement).
2.3 Time Period
The temporal scope of our review was as follows:
• Pending matters: All litigation, governmental investigations, regulatory proceedings, and compliance matters that are pending or open as of the date of this memorandum (April 18, 2025).
• Resolved matters: Matters that were resolved, settled, dismissed, or otherwise concluded within the three-year period preceding the date of this memorandum (i.e., since April 2022) were reviewed for pattern and recurrence assessment purposes, as well as for potential relevance to representations and disclosure schedule requirements.
• Threatened claims: Demand letters, cease-and-desist notices, pre-litigation communications, and other indications of threatened claims received within the 24-month period preceding the date of this memorandum (i.e., since April 2023) were reviewed and assessed.
2.4 Limitations. The findings and assessments contained in this memorandum are subject to the following limitations, which should be considered in evaluating our conclusions:
Reliance on Produced Materials. Our review is based on the materials produced by the Company and its counsel in the VDR, the supplemental responses provided by Caldwell, Raines & Sheppard LLP, and the information obtained through management interviews. While we conducted sampled independent docket checks for U.S. litigation matters, we did not conduct a comprehensive independent investigation or verification of all court records, regulatory filings, or other public records across all jurisdictions. We have relied on the completeness and accuracy of the materials produced by the Company and the representations made by management, subject to the verification steps described herein.
Privilege. Certain internal legal memoranda, attorney-client privileged communications, and attorney work product of the Company and its counsel were not produced in the VDR, and we have respected the Company's assertion of attorney-client privilege over such materials. As a result, our review may not encompass the full universe of internal legal analyses, risk assessments, or settlement evaluations that may exist within the Company's files. We understand that Caldwell, Raines & Sheppard LLP has confirmed that no materials responsive to our Request List have been withheld on the basis of privilege other than those identified on the privilege log delivered on April 7, 2025 (listing 47 documents).
Foreign-Jurisdiction Matters. For matters arising under the laws of Switzerland, Germany, Singapore, and the United Kingdom, our review was conducted in coordination with the following local counsel firms, upon whom we have relied for legal analysis under their respective jurisdictions:
• Switzerland: Breitfeld Hess & Partner AG, Glenrock Assurance (Dr. Lukas Breitfeld, lead partner). Dr. Breitfeld's firm has provided a separate local counsel due diligence report dated April 14, 2025, which we have reviewed and incorporated into our analysis.
• Germany: Wendt Schäfer Rechtsanwälte PartG mbB, Munich (Dr. Katarina Wendt, lead partner). Dr. Wendt's firm has provided a separate local counsel due diligence report dated April 15, 2025, which we have reviewed and incorporated into our analysis.
• Singapore: Tan Liang & Associates LLP, Singapore (Kelvin Tan, lead partner). Mr. Tan's firm has provided a separate local counsel due diligence report dated April 12, 2025, which we have reviewed and incorporated into our analysis.
• United Kingdom: Calderwood & Harkness LLP's London office (Catherine Ashford, counsel) reviewed the UK matters directly.
Ongoing Matters. The status of pending litigation and regulatory matters is inherently dynamic and may change at any time. The assessments contained in this memorandum reflect the status of matters as of April 18, 2025, and should be updated periodically as the transaction progresses toward closing.
3. Pending Litigation
3.1 United States Litigation
3.1.1 Commercial Contract Disputes. We identified three pending commercial contract disputes involving Luminex US. Each is summarized below, with additional detail provided in Exhibit A.
Paragon Procurement Solutions Inc. v. Luminex Systems Inc. (E.D. Va., Case No. 1:24-cv-01387-TSE, filed September 6, 2024). Paragon Procurement Solutions Inc. ("Paragon"), a former channel partner and reseller of the Luminex One platform, filed suit against Luminex US alleging breach of a Value-Added Reseller Agreement dated June 15, 2021, as amended (the "Paragon VAR Agreement"). Paragon alleges that Luminex US wrongfully terminated the Paragon VAR Agreement effective July 31, 2024, in retaliation for Paragon's development of a competing procurement tool, and that Luminex US misappropriated certain customization code developed by Paragon under the VAR Agreement. Paragon asserts claims for breach of contract, misappropriation of trade secrets under the Defend Trade Secrets Act (18 U.S.C. § 1836) and the Virginia Trade Secrets Act (Va. Code § 59.1-336 et seq.), tortious interference with business expectancy, and unjust enrichment. Paragon seeks compensatory damages of $18.7 million (representing the alleged value of lost commissions over the remaining term of the VAR Agreement), plus additional damages of $4.7 million for the alleged trade secret misappropriation, for aggregate claims of approximately $23.4 million.
Luminex US filed an answer and counterclaim on November 12, 2024, denying the material allegations and asserting counterclaims for breach of the non-compete provisions of the Paragon VAR Agreement and for misuse of Luminex confidential information in developing Paragon's competing product. Luminex US seeks injunctive relief and compensatory damages of approximately $8.2 million on its counterclaim. Fact discovery is currently open, with an exchange of initial disclosures completed on January 15, 2025. The discovery deadline is set for September 30, 2025, with a trial date of February 9, 2026.
Assessment: Based on our review of the Paragon VAR Agreement, the termination notice, and the pleadings, we believe Luminex US has meritorious defenses to Paragon's claims, particularly with respect to the trade secret misappropriation claim, for which Paragon will need to identify the specific trade secrets allegedly misappropriated with reasonable particularity. However, the breach of contract claim presents moderate risk, as the termination provisions of the Paragon VAR Agreement contain a "for cause" termination standard that is susceptible to differing interpretations. Luminex's in-house counsel, Priya Ramanathan, has informed us that Luminex US has reserved $4.5 million against this matter, which we view as reasonable at this stage. This matter warrants disclosure on Schedule 3.9 (Litigation) and should be flagged for the R&W insurance application. In addition, the Paragon VAR Agreement is one of the approximately 340 commercial contracts subject to our change-of-control consent analysis; the VAR Agreement contains a consent requirement upon a "change of control" of Luminex US, which will be triggered by the Merger. See the Material Contracts Review Memorandum for our detailed analysis.
Brightline Technologies LLC v. Luminex Systems Inc. (D. Del., Case No. 1:25-cv-00102-MN, filed January 17, 2025). Brightline Technologies LLC ("Brightline"), a Delaware limited liability company, filed suit against Luminex US alleging breach of a Software Implementation Agreement dated March 3, 2023 (the "Brightline SIA"). Brightline alleges that Luminex US failed to deliver certain custom integration features on the timeline specified in the Brightline SIA and that the delivered features contained material defects, resulting in Brightline's inability to deploy the Luminex One platform as planned. Brightline asserts claims for breach of contract and breach of the implied warranty of merchantability, seeking compensatory damages of $3.8 million (representing the cost of the implementation plus consequential damages for business disruption).
Luminex US filed its answer on March 3, 2025, denying the material allegations and asserting affirmative defenses including failure to mitigate damages, contributory fault of Brightline's IT team in the integration process, and the contractual limitation of liability in the Brightline SIA, which caps Luminex's aggregate liability at the fees paid by Brightline in the 12 months preceding the claim (approximately $1.2 million). The case is in the early stages of litigation; a scheduling conference is set for May 5, 2025.
Assessment: We view this matter as presenting limited risk to Luminex US, primarily because of the contractual limitation of liability clause, which, if enforced, would cap Luminex's exposure at approximately $1.2 million. Delaware courts generally enforce contractual limitation of liability provisions in commercial contracts between sophisticated parties. Luminex's in-house counsel has informed us that Luminex US has reserved $750,000 against this matter. We view this reserve as reasonable and potentially conservative given the strength of the contractual limitation defense. This matter warrants disclosure on Schedule 3.9 (Litigation) but is not expected to require specific attention in the R&W insurance application.
Luminex Systems Inc. v. Tidewater Analytics Corp. (Circuit Court of Fairfax County, Virginia, Case No. CL-2024-0014782, filed October 22, 2024). This is a claim brought by Luminex US against Tidewater Analytics Corp. ("Tidewater"), a Virginia corporation, for breach of a Data Services Agreement dated February 1, 2022, and for declaratory judgment regarding Luminex's rights to certain data analytics outputs generated through the Tidewater platform using Luminex-provided data sets. Luminex US seeks compensatory damages of $2.1 million and a declaratory judgment confirming Luminex's ownership of the disputed analytics outputs. Tidewater filed an answer and counterclaim on December 18, 2024, asserting counterclaims for breach of contract and conversion, seeking $1.4 million in compensatory damages. Discovery is in progress.
Assessment: We view this matter as presenting modest exposure on the counterclaim, with potential upside recovery on Luminex's affirmative claims. The primary risk relates to the ownership of the analytics outputs, which implicates the Company's IP portfolio. We have coordinated our analysis of this matter with the IP & Technology team, and their assessment is incorporated in the IP & Technology Due Diligence Summary Memorandum. Luminex's in-house counsel has informed us that no reserves have been booked against the Tidewater counterclaim, given management's assessment that the counterclaim lacks merit. We recommend booking a nominal reserve of $500,000 as a precautionary measure. This matter warrants disclosure on Schedule 3.9.
3.1.2 Employment Litigation. We identified two pending employment-related matters involving Luminex US.
Martinez v. Luminex Systems Inc. (Superior Court of California, County of Santa Clara, Case No. 24-CV-378291, filed August 14, 2024). Sarah Martinez, a former Senior Product Manager in Luminex US's San Jose office, filed suit alleging wrongful termination in violation of public policy, retaliation under California Labor Code § 1102.5, and gender discrimination under the California Fair Employment and Housing Act (FEHA), Cal. Gov't Code § 12940. Martinez alleges that she was terminated in June 2024 after raising concerns internally about alleged gender-based pay disparities within the Product Management department and after making a complaint to her manager regarding what she characterized as a hostile work environment. Martinez seeks compensatory damages, emotional distress damages, punitive damages, and attorneys' fees, without specifying a total amount in the complaint. Based on our review of similar FEHA claims involving technology companies, we estimate the range of potential exposure to be $750,000 to $3,000,000 (inclusive of attorneys' fees), with a most likely outcome in the range of $1,000,000 to $1,500,000 assuming the case proceeds to trial.
Luminex US filed a demurrer on October 7, 2024, which was overruled on December 12, 2024. An answer was filed on January 9, 2025. The case is currently in written discovery, with depositions scheduled to begin in June 2025. The parties attended a mandatory mediation session on March 19, 2025, which did not result in a settlement. A second mediation session is tentatively scheduled for July 2025.
Assessment: Individual employment claims of this nature are routine for a technology company with approximately 1,650 U.S. employees. However, we note that the underlying allegations regarding gender-based pay disparities could serve as a predicate for a broader class or collective action if additional claimants come forward. During our management interview with Priya Ramanathan on April 3, 2025, Ms. Ramanathan confirmed that Luminex US engaged an independent compensation consultant (Meridian Compensation Partners LLC) in Q4 2024 to conduct a pay equity analysis. The analysis, which was completed in January 2025, identified certain statistically significant pay gaps in three job categories within the Product Management and Engineering departments. Luminex US has implemented salary adjustments for affected employees totaling approximately $1.8 million in aggregate annual compensation increases. We recommend that this matter, along with the pay equity analysis results and remediation steps, be disclosed on Schedule 3.9 and discussed with Ashbury Risk Advisors LLC in connection with the R&W insurance application. Luminex US has reserved $1.2 million against this matter.
Additionally, we note that Luminex US has received a Charge of Discrimination filed by a former Sales Director, Robert Callaway, with the U.S. Equal Employment Opportunity Commission ("EEOC"), Austin District Office (Charge No. 450-2025-01284), received by Luminex US on February 21, 2025. Mr. Callaway alleges age discrimination under the Age Discrimination in Employment Act in connection with his termination in November 2024. Luminex US filed its Position Statement with the EEOC on April 1, 2025. No litigation has been filed. Based on our review of the Position Statement and the underlying facts, we view this charge as presenting low to moderate risk. Luminex US has not booked reserves against this matter. We recommend disclosure on Schedule 3.9.
We did not identify any pending class or collective action wage-and-hour claims against Luminex US. We note that Luminex US classifies its software engineers, product managers, and other technical employees as exempt under the Fair Labor Standards Act and applicable state wage-and-hour laws. During our management interview, Ms. Ramanathan confirmed that Luminex US engaged outside counsel (Hartfield Burke LLP) in 2023 to conduct an exemption classification audit, which concluded that Luminex US's classification practices are generally consistent with applicable law, with limited reclassification recommendations that have been implemented. We did not identify any pending inquiries from the U.S. Department of Labor or any state wage-and-hour enforcement agency.
3.1.3 intellectual Property Litigation. We identified one pending IP-related matter directly involving Luminex US, plus one matter that implicates Luminex technology indirectly.
NexGen Innovations Ltd. v. Luminex Systems Inc. (W.D. Tex., Waco Division, Case No. 6:24-cv-00893-ADA, filed July 22, 2024). NexGen Innovations Ltd. ("NexGen"), a non-practicing entity incorporated in Ireland and operating primarily through a litigation funding arrangement, filed suit against Luminex US alleging infringement of U.S. Patent No. 10,482,317 (the "'317 Patent"), entitled "System and Method for Automated Procurement Workflow Optimization Using Machine Learning." NexGen alleges that certain machine-learning-based workflow optimization features of the Luminex One platform infringe Claims 1, 4, 7, and 12 of the '317 Patent. NexGen seeks compensatory damages in the form of a reasonable royalty, which NexGen's preliminary damages expert report estimates at $12.5 million to $18.0 million, and injunctive relief.
Luminex US filed its answer on October 14, 2024, denying infringement and asserting affirmative defenses of non-infringement, invalidity (anticipation and obviousness under 35 U.S.C. §§ 102 and 103 based on prior art identified through the Company's internal review and a prior art search conducted by Luminex US's patent counsel, Fisher Daniels LLP), and patent exhaustion. Luminex US has also filed inter partes review ("IPR") petitions with the U.S. Patent Trial and Appeal Board challenging the validity of Claims 1, 4, 7, and 12 (IPR Case Nos. IPR2025-00341 and IPR2025-00342, filed January 21, 2025). Institution decisions on the IPR petitions are expected by approximately July 21, 2025. A Markman hearing in the district court case is scheduled for June 16, 2025.
Assessment: Patent litigation brought by non-practicing entities is a common occurrence in the enterprise software industry, and the Western District of Texas, Waco Division, is a well-known forum for such actions. Based on our review of the claims, the preliminary claim construction positions, and the prior art identified by Fisher Daniels LLP, we believe Luminex US has strong invalidity defenses, particularly with respect to the prior art references identified in the IPR petitions. If the PTAB institutes review and ultimately finds Claims 1, 4, 7, and 12 unpatentable, this case would likely be resolved in Luminex's favor. However, patent litigation is inherently uncertain, and the damages range asserted by NexGen's expert, while inflated in our view, represents a non-trivial exposure. Luminex US has reserved $5.0 million against this matter. We view this reserve as reasonable. This matter is addressed in greater detail in the IP & Technology Due Diligence Summary Memorandum and should be disclosed on Schedule 3.9. We also recommend that it be specifically identified in the R&W insurance application, as Grandview Specialty may seek a specific exclusion or sub-limit for this matter.
We also note that a separate patent infringement claim, DataForge Systems Inc. v. Cloudvault Technologies Inc. et al. (N.D. Cal., Case No. 3:24-cv-06172-WHO), names Cloudvault Technologies Inc. ("Cloudvault") as a defendant. Cloudvault is a cloud infrastructure provider that hosts a significant portion of the Luminex One platform. While Luminex US is not named as a defendant, the patents at issue (U.S. Patent Nos. 11,237,891 and 11,412,008) relate to cloud-based data processing architectures. In the event that Cloudvault is found to infringe and is enjoined from using the patented methods, there could be downstream effects on Luminex's cloud hosting arrangements. We have reviewed the Luminex-Cloudvault Master Services Agreement and note that it contains an IP indemnification clause running from Cloudvault to Luminex. We recommend monitoring this matter but do not believe it requires disclosure on the disclosure schedules at this time.
We did not identify any pending trade secret misappropriation claims against Luminex US other than the Paragon matter discussed in Section 3.1.1 above, which includes trade secret allegations. Luminex US has obtained freedom-to-operate opinions from Fisher Daniels LLP covering the core modules of the Luminex One platform (most recent opinion dated November 2024). These opinions are addressed in the IP & Technology Due Diligence Summary Memorandum.
3.1.4 Government Contract Disputes. We did not identify any pending bid protests, contract disputes under the Contract Disputes Act, False Claims Act investigations, or qui tam actions relating to any of Luminex US's federal government contracts. Luminex US currently holds the following principal federal contracts:
• U.S. Department of Defense: Contract No. W91QUZ-22-C-0047 (DOD logistics software module for the Defense Logistics Agency), awarded September 2022, period of performance through September 2027, aggregate contract value approximately $42 million. This is a firm-fixed-price contract.
• U.S. Department of Energy: Blanket Purchase Agreement No. DE-BP36-23LN00014 (procurement platform for DOE procurement operations), effective March 2023, aggregate estimated value approximately $18 million over a five-year period.
• U.S. General Services Administration: GSA Schedule 70 (now consolidated into the Multiple Award Schedule), Contract No. GS-35F-0182Y, effective through April 2028, providing for the sale of the Luminex One platform and related professional services to federal civilian agencies.
During our management interview with Thomas Vickers (VP, Government Programs) on April 7, 2025, Mr. Vickers confirmed that Luminex US has not received any False Claims Act subpoenas, civil investigative demands, or qui tam notifications within the past five years. Mr. Vickers also confirmed that Luminex US has not been the subject of any DCIS (Defense Criminal Investigative Service) or Inspector General investigation during this period. We reviewed the DCAA audit history for the DOD contract and note that Luminex US underwent a DCAA incurred cost audit for fiscal year 2023, which was completed in October 2024 with no material findings. A DCAA audit for fiscal year 2024 is anticipated but has not yet been initiated.
We note that the DOD contract and the DOE BPA are relevant to the CFIUS review of the proposed acquisition (Tracking No. CFIUS-2025-0087). The DOD contract involves Controlled Unclassified Information ("CUI") and requires compliance with NIST SP 800-171 cybersecurity standards. Luminex US does not currently hold a facility security clearance and does not handle classified information. These matters are discussed further in Section 10.1 below and in the context of the government contract compliance assessment in Section 6.4.
Assessment: The absence of pending government contract disputes is a favorable finding. However, we recommend that the government contracts be carefully reviewed in connection with the CFIUS filing, and that the change-of-control implications of each government contract be analyzed (see Material Contracts Review Memorandum). The DOD contract and DOE BPA each contain assignment and novation clauses that may require government consent in connection with the Merger. Mr. Vickers has confirmed that Luminex US intends to seek consent from the contracting officers as part of the transaction process.
3.2 Swiss Litigation
Based on our review of the VDR materials and the local counsel due diligence report prepared by Breitfeld Hess & Partner AG (Dr. Lukas Breitfeld), we identified one pending matter involving Luminex Systems AG (Bahnhofstrasse 71, 8001 Zürich).
Employment Claim — Former Sales Director. A former Sales Director of Luminex Systems AG, Henrik Dalmqvist, filed a claim with the Glenrock Assurance Labor Court (Arbeitsgericht Zürich) in November 2024 (Case No. AG240987), alleging wrongful termination and seeking damages of CHF 380,000 (approximately $428,000 at current exchange rates), representing six months' salary plus bonus entitlement and alleged violations of the notice period provisions under the Swiss Code of Obligations (Art. 335-335c CO). Mr. Dalmqvist was employed by Luminex AG from April 2019 until his termination in August 2024. The Company contends that Mr. Dalmqvist was terminated for cause following repeated violations of the Company's expense reimbursement policies. A conciliation hearing was held on February 12, 2025, and did not result in a settlement. The matter has been referred for adjudication; a hearing date has not yet been scheduled.
Assessment: Dr. Breitfeld has advised that the Company's position is defensible, though Swiss labor courts tend to be protective of employee rights, and there is a risk that the court could find the termination procedurally deficient or the cause insufficient, resulting in an award of severance compensation under Art. 337c CO. Dr. Breitfeld estimates the probable range of exposure at CHF 150,000 to CHF 300,000. Luminex AG has reserved CHF 200,000 against this matter. We view this reserve as reasonable. This matter should be disclosed on Schedule 3.9 but is not material in the context of the transaction.
We did not identify any other pending commercial disputes or regulatory proceedings involving Luminex Systems AG before Swiss courts.
3.3 German Litigation
Based on our review of the VDR materials and the local counsel due diligence report prepared by Wendt Schäfer Rechtsanwälte PartG mbB (Dr. Katarina Wendt), we identified two pending matters involving Luminex Systems GmbH (Leopoldstrasse 120, 80802 Munich, HRB 247891).
Works Council Dispute — Consultation Regarding Restructuring. In connection with a planned reorganization of the Munich office engineering team, Veltronix GmbH initiated consultations with its works council (Betriebsrat) in October 2024. The proposed reorganization would involve the elimination of 12 positions (out of approximately 210 total employees at the Munich office) and the creation of 8 new positions with modified job descriptions. The works council has contested the adequacy of the consultation process and has filed an application with the Munich Labor Court (Arbeitsgericht München, Case No. 14 BV 8247/25, filed February 3, 2025) seeking a temporary injunction to prevent the implementation of the reorganization until a social plan (Sozialplan) has been agreed or imposed by arbitration. A hearing on the injunction application is scheduled for May 14, 2025.
Assessment: Dr. Wendt has advised that the works council's application has a reasonable likelihood of success with respect to the temporary injunction, as German labor courts routinely require employers to complete the consultation process, including negotiation of a social plan, before implementing restructurings that affect more than a de minimis number of employees. If the injunction is granted, the reorganization will be delayed until a social plan is agreed or imposed. Dr. Wendt estimates the cost of a social plan in the range of €450,000 to €800,000, depending on the outcome of negotiations. More significantly for the transaction, the pending works council dispute should be considered in the context of any post-closing workforce integration or restructuring plans. We recommend that Ardent's management team coordinate with Dr. Wendt to ensure compliance with German co-determination requirements in connection with any planned post-closing changes. Veltronix GmbH has reserved €500,000 for this matter.
Commercial Claim — Rhein-Main Industrieberatung GmbH. Rhein-Main Industrieberatung GmbH ("RMI"), a German consulting firm, filed a claim in the Sundial Assurance Court (Landgericht München I, Case No. 10 HK O 21487/24, filed December 11, 2024) alleging breach of a consulting agreement dated May 2023. RMI claims it is owed €285,000 in unpaid consulting fees for services allegedly rendered in connection with a Veltronix GmbH customer implementation project. Veltronix GmbH filed its statement of defense on March 14, 2025, contesting the claim on the grounds that RMI failed to meet certain deliverable milestones and that the disputed fees were properly withheld pursuant to the performance-based payment provisions of the consulting agreement.
Assessment: Dr. Wendt assesses this claim as presenting moderate risk, with a probable range of exposure of €100,000 to €200,000, reflecting the likelihood that the court may find partial performance by RMI entitling it to proportional payment. Veltronix GmbH has reserved €150,000. We view this reserve as reasonable. This matter should be disclosed on Schedule 3.9 but is not material.
3.4 United Kingdom Litigation
Based on our review of the VDR materials and the analysis conducted by Catherine Ashford of Calderwood & Harkness LLP's London office, we identified one pending matter involving Luminex Systems UK Ltd. (14 Broadwick Street, London W1F 8HN, Company No. 12847362).
Employment Tribunal Claim — Former Marketing Manager. Jennifer Whitfield, a former Marketing Manager of Luminex UK, filed a claim with the London Central Employment Tribunal (Case No. 2200145/2025, filed January 8, 2025) alleging unfair dismissal under the Employment Rights Act 1996 and disability discrimination under the Equality Act 2010. Ms. Whitfield alleges that her dismissal in October 2024 was related to a period of long-term sickness absence associated with a chronic medical condition and that Luminex UK failed to make reasonable adjustments to accommodate her disability. She seeks compensation for unfair dismissal (basic and compensatory awards) and damages for disability discrimination, including injury to feelings. Based on comparable Employment Tribunal awards, we estimate the total potential exposure in the range of £80,000 to £200,000.
A preliminary hearing for case management purposes took place on March 27, 2025. The full merits hearing is listed for three days commencing September 15, 2025. ACAS early conciliation was attempted prior to the filing of the claim but was unsuccessful.
Assessment: Catherine Ashford has advised that the Company faces moderate risk on both the unfair dismissal and disability discrimination claims. The key issue will be whether Luminex UK can demonstrate that it followed a fair procedure and gave adequate consideration to reasonable adjustments before proceeding to dismissal. Luminex UK has reserved £120,000 against this matter. We view this reserve as reasonable. This matter should be disclosed on Schedule 3.9 but is not material in the context of the transaction.
We did not identify any other pending commercial disputes or regulatory proceedings involving Luminex UK.
3.5 Singapore Litigation
Based on our review of the VDR materials and the local counsel due diligence report prepared by Tan Liang & Associates LLP (Kelvin Tan), we did not identify any pending litigation or arbitration proceedings involving Luminex Systems Pte. Ltd. (8 Marina Boulevard, #36-01, Singapore 018981, UEN 201924781K). Mr. Tan has confirmed that a search of the Singapore courts' electronic filing system did not reveal any proceedings naming Luminex Systems Pte. Ltd. as a party.
Assessment: The absence of pending litigation in Singapore is a favorable finding and is consistent with the relatively small scale of the Singapore operations (approximately 85 employees, FY 2024 Singapore revenue of approximately SGD 28 million).
4. Threatened Litigation and Pre-Litigation Disputes
4.1 Demand Letters and Cease-and-Desist Notices
Our review of the VDR materials and the Company's Litigation Log identified the following demand letters, cease-and-desist notices, and pre-litigation communications received by Luminex Group entities within the past 24 months:
Cascade Data Solutions LLC — Demand Letter (December 6, 2024). Luminex US received a demand letter from Cascade Data Solutions LLC ("Cascade"), a data integration services provider based in Portland, Oregon, asserting that Luminex US breached a Strategic Alliance Agreement dated January 15, 2023, by failing to provide Cascade with the contractually guaranteed minimum number of customer referrals during the 2024 calendar year. Cascade demands payment of $1.2 million, representing the alleged shortfall in referral fees. Luminex US, through Caldwell, Raines & Sheppard LLP, responded on January 10, 2025, disputing the claim and asserting that the referral targets were aspirational goals subject to market conditions, not guaranteed minimums. Cascade's counsel responded on February 14, 2025, reiterating the demand and threatening litigation if the matter was not resolved by March 31, 2025. As of the date of this memorandum, no lawsuit has been filed. We understand from Priya Ramanathan that Luminex US has engaged in informal settlement discussions with Cascade, offering a payment of $300,000 in exchange for a full release and termination of the Strategic Alliance Agreement. No agreement has been reached.
Assessment: We view the likelihood of this matter escalating to formal litigation as moderate. If Cascade proceeds, the potential exposure is limited to the range of $300,000 to $1.2 million. We have reviewed the Strategic Alliance Agreement and note that it contains a mandatory arbitration clause (AAA Commercial Arbitration Rules, to be conducted in Reston, Virginia). Luminex US has not booked reserves against this matter. We recommend booking a reserve of $400,000 and disclosing the matter on Schedule 3.9.
IP Assertion Letter — Vertex Analytics Inc. (March 3, 2025). Luminex US received a letter from patent licensing firm Velthorn Patent Group LLC, acting on behalf of Vertex Analytics Inc. ("Vertex"), asserting that the Luminex One platform's predictive analytics features infringe U.S. Patent No. 11,671,432 and U.S. Patent No. 11,823,907 (collectively, the "Vertex Patents"). The letter requests that Luminex enter into a licensing agreement covering the Vertex Patents and suggests a royalty rate of 2.5% of revenues attributable to the predictive analytics features. The letter does not specify a damages amount or threaten litigation explicitly, but states that "Vertex reserves all rights to enforce its intellectual property interests."
Luminex US has engaged Fisher Daniels LLP to review the Vertex Patents and prepare a preliminary non-infringement and invalidity analysis. The analysis is expected to be completed by May 15, 2025. No response to the Velthorn Patent Group letter has been sent pending completion of the Fisher Daniels analysis.
Assessment: Patent assertion letters from licensing firms are common in the enterprise software industry. Based on our preliminary review of the Vertex Patents (which we have coordinated with the IP & Technology team), we note that the claims appear to be directed to a general-purpose predictive analytics methodology that may be broadly applicable but may also lack novelty in light of prior art. We recommend completing the Fisher Daniels analysis before responding and, depending on the results, either engaging in licensing discussions or sending a detailed rebuttal. This matter is not yet a pending litigation and may not require disclosure on Schedule 3.9, but we recommend mentioning it in the R&W insurance application to avoid any later assertion that it was a known but undisclosed matter. No reserves have been booked.
Former Employee Cease-and-Desist — Marcus Liu (August 22, 2024). Luminex US's Human Resources department received a cease-and-desist letter from an attorney representing Marcus Liu, a former Senior Software Engineer in the San Francisco office, alleging that Luminex US improperly withheld Mr. Liu's final paycheck for three days beyond the deadline required by California Labor Code § 202 and failed to pay accrued but unused vacation time as required by California Labor Code § 227.3. The letter demands payment of $14,200 (representing waiting time penalties and the alleged vacation pay shortfall). Luminex US's HR department investigated the matter and determined that a payroll processing error resulted in a two-day delay. Luminex US paid the outstanding vacation balance and a goodwill payment of $5,000 on September 15, 2024. Mr. Liu's counsel responded on October 4, 2024, requesting additional waiting time penalties. No further communication has been received since October 2024.
Assessment: We view this matter as de minimis and unlikely to escalate further. No reserves have been booked, and no disclosure is required.
Tolling Agreements. We reviewed the VDR materials and management questionnaires for any tolling agreements or standstill arrangements. We identified one tolling agreement: a tolling agreement dated November 15, 2024, between Luminex US and Nexus Workforce Solutions Inc. ("Nexus"), tolling the statute of limitations on a potential claim by Nexus related to alleged over-billing under a staffing services agreement. The tolling agreement has been extended once and currently runs through June 30, 2025. Luminex US's position, as confirmed by Priya Ramanathan, is that the over-billing allegations are without merit and that the tolling agreement was entered into to allow the parties time to review the billing records and reach a resolution without litigation. The disputed amount is approximately $420,000. We recommend disclosure of the tolling agreement on Schedule 3.9.
4.2 Internal Assessments of Potential Claims
During our management interviews and review of the auditor communications, we identified the following matters that the Company's management has internally assessed as potential future claims but that have not been formalized as demands or proceedings:
Potential Customer Claim — Horizon Health Systems. During our interview with Annelise Gruber (CFO) on April 4, 2025, Ms. Gruber disclosed that Luminex US is in active discussions with Horizon Health Systems ("Horizon"), a large healthcare sector customer, regarding alleged performance deficiencies in the Luminex One platform's integration with Horizon's existing ERP system (Bramwell Data Systems). Horizon has informally threatened to seek credits or refunds of approximately $5.8 million, representing approximately 18 months of subscription fees, if the integration issues are not resolved. Luminex US has deployed a dedicated technical team to address the issues, and Ms. Gruber expressed confidence that the issues can be resolved through the ongoing remediation efforts. No formal demand letter has been received, and no litigation has been threatened in writing. However, Ms. Gruber noted that Horizon's Chief Procurement Officer has verbally indicated that Horizon may seek outside counsel to evaluate its options if the issues are not resolved by Q3 2025.
Assessment: We view this as a significant customer relationship risk that could, if it escalates, result in a material claim. We recommend that this matter be disclosed on Schedule 3.9 as a threatened or potential claim. We also recommend that the Ardent deal team monitor this matter closely through closing and that the interim operating covenants be reviewed to ensure that any settlement or credit arrangement with Horizon above the applicable threshold is subject to Buyer's consent. Hargrove Thornton LLP (Margaret Dawson) has noted this matter in the management representation letter as an unrecorded contingency with respect to the FY 2024 audit.
Potential Regulatory Inquiry — California Consumer Privacy Act. Luminex US's Chief Privacy Officer, Dr. Ingrid Sørensen, disclosed during a supplemental written response dated April 9, 2025, that Luminex US received an informal inquiry from the California Attorney General's office in January 2025 regarding the Company's CCPA/CPRA opt-out mechanism on the Luminex One platform's customer-facing portal. The inquiry consisted of a questionnaire requesting information about the Company's data collection and opt-out practices. Luminex US responded to the questionnaire on February 28, 2025. No further communication has been received from the California AG. Dr. Sørensen noted that Luminex US has engaged Brightman Duffy & Associates (a privacy consulting firm) to conduct a comprehensive review of the Company's CCPA/CPRA compliance posture, with findings expected by May 2025.
Assessment: Informal inquiries from the California AG regarding CCPA/CPRA compliance have become increasingly common across the technology sector. At this stage, the inquiry does not appear to be an enforcement action, but it could escalate. We recommend disclosing this matter on Schedule 3.10 (Compliance with Laws) and monitoring for any follow-up from the California AG. This matter is also relevant to the data privacy compliance assessment in Section 6.2 below.
5. Governmental Investigations and Regulatory Proceedings
5.1 U.S. Federal Agencies
5.1.1 Department of Justice / Federal Trade Commission. We did not identify any pending investigation of any Luminex Group entity by the U.S. Department of Justice or the Federal Trade Commission. Our review of the VDR materials, management questionnaires, and auditor communications did not reveal any current or prior DOJ or FTC subpoenas, civil investigative demands, or second requests directed at Luminex (other than in connection with the pending acquisition).
HSR Filing Context. The pending acquisition is subject to pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The Notification and Report Form was filed on March 28, 2025 (Transaction No. HSR-20250328-4192). The DOJ and FTC completed their clearance process on April 2, 2025, with the FTC designated as the reviewing agency. The initial 30-day waiting period is scheduled to expire on April 28, 2025, unless the FTC issues a Second Request for Additional Information and Documentary Material prior to that date.
We note that the combined post-acquisition market share in the procurement-automation SaaS segment is estimated at approximately 25% (Luminex ~18% + Vectis Solutions LLC ~7%). Vectis Solutions LLC is a portfolio company of Ardent Capital Partners II LP (Ardent's predecessor fund), with 2024 revenue of approximately $68 million and CEO Michael Parekh. While the 25% combined market share does not, in itself, trigger a presumption of competitive harm under the revised 2023 Merger Guidelines, it is sufficient to attract scrutiny from the FTC, particularly given recent FTC interest in concentration in SaaS markets. We recommend close coordination with Elaine Forsythe (Antitrust & Competition) on this matter and note that a Second Request is anticipated. See Section 10.2 for additional detail.
Prior FTC/DOJ Inquiries. We reviewed the VDR materials for any record of prior FTC or DOJ inquiries regarding Luminex's competitive practices. We identified one prior matter: in 2021, the FTC sent a Civil Investigative Demand to Luminex US in connection with the FTC's broader market study of the procurement software industry (FTC File No. P214500). Luminex US cooperated with the CID and produced responsive documents. The market study was concluded in 2022, and the FTC published a report in January 2023 without identifying any enforcement action against Luminex. No further inquiry from the FTC has been received.
5.1.2 Securities and Exchange Commission. Luminex Holdings is a privately held Delaware corporation and is not a reporting company under the Securities Exchange Act of 1934. However, Luminex Holdings has issued securities in private placements exempt from registration under Regulation D of the Securities Act of 1933. We reviewed the Company's Form D filings with the SEC and identified filings in connection with equity issuances in 2019 (Series B Preferred Stock), 2020 (Series C Preferred Stock), and 2022 (convertible notes). All Form D filings appear to have been timely filed.
We did not identify any SEC inquiries, comment letters, investigation notices, or enforcement actions directed at Luminex Holdings or any of its subsidiaries. During our management interview, Priya Ramanathan confirmed that the Company has not received any communications from the SEC Division of Enforcement or the Division of Corporation Finance within the past five years.
5.1.3 Department of Defense / DCIS / Inspector General. As noted in Section 3.1.4 above, we did not identify any pending or past investigations by the Defense Criminal Investigative Service, the DOD Inspector General, or any other DOD investigative body relating to Luminex US's government contracts. We reviewed the DCAA audit history and confirmed that the most recent audit (FY 2023 incurred cost audit, completed October 2024) resulted in no material findings.
Thomas Vickers confirmed that Luminex US has never been suspended or debarred from government contracting, has never been listed on the System for Award Management (SAM) exclusion list, and has never received a "cure notice" or "show cause" notice under any of its government contracts. We verified this representation through an independent SAM.gov search conducted on April 16, 2025.
5.1.4 Internal Revenue Service. We reviewed the VDR materials for any pending IRS audits, examinations, or disputes involving Luminex Holdings (EIN: 86-2547193) or Luminex US (EIN: 86-2547210).
Current IRS Examination. Luminex Holdings is currently subject to an IRS Large Business and International ("LB&I") division examination for the tax years 2021 and 2022. The examination was initiated in September 2024 and is being conducted by IRS Revenue Agent Patricia Kowalski (Employee ID: 47-821394) out of the IRS's LB&I Mid-Atlantic field office. The primary focus of the examination is the intercompany royalty arrangement between Luminex Systems AG and Luminex US, under which Luminex US pays royalties to Luminex AG at a rate of 4.5% of U.S. net revenues for the license of intellectual property rights underlying the Luminex One platform. The IRS has requested documentation supporting the arm's-length nature of the royalty rate, including the contemporaneous transfer pricing documentation and the transfer pricing study prepared by Pendleton & Associates LLP.
Annelise Gruber confirmed during our management interview that